Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

About Vanda Pharmaceuticals

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VNDA
  • CUSIP: 92165910
Key Metrics:
  • Previous Close: $14.50
  • 50 Day Moving Average: $14.13
  • 200 Day Moving Average: $15.20
  • 52-Week Range: $6.95 - $18.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -98.93
  • P/E Growth: -1.54
  • Market Cap: $614.19M
  • Outstanding Shares: 43,968,000
  • Beta: 1.42
Profitability:
  • Net Margins: -23.07%
  • Return on Equity: -16.13%
  • Return on Assets: -9.84%
Debt:
  • Current Ratio: 3.36%
  • Quick Ratio: 3.35%
Additional Links:
Companies Related to Vanda Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (54.03% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017Jefferies Group LLCSet Price TargetBuy$21.00View Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00View Rating Details
10/24/2016Piper Jaffray CompaniesSet Price TargetBuy$19.00View Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00View Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00View Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017        
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.04)($0.04)($0.04)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.04)($0.04)($0.04)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Ownership Percentage: 8.45%
Institutional Ownership Percentage: 95.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.00View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateHeadline
finance.yahoo.com logoVANDA PHARMACEUTICALS INC. Financials (NASDAQ:VNDA)
finance.yahoo.com - February 23 at 3:17 AM
capitalcube.com logoVanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 (NASDAQ:VNDA)
www.capitalcube.com - February 22 at 11:54 AM
News IconVanda Pharmaceuticals Inc VNDA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:VNDA)
www.bioportfolio.com - February 21 at 8:16 AM
capitalcube.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : February 21, 2017 (NASDAQ:VNDA)
www.capitalcube.com - February 21 at 8:15 AM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results - Earnings Call Transcript (NASDAQ:VNDA)
seekingalpha.com - February 17 at 5:04 PM
biz.yahoo.com logoQ4 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:VNDA)
us.rd.yahoo.com - February 17 at 5:04 PM
us.rd.yahoo.com logoVanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results (NASDAQ:VNDA)
us.rd.yahoo.com - February 17 at 5:04 PM
biz.yahoo.com logoVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:VNDA)
us.rd.yahoo.com - February 17 at 5:04 PM
biz.yahoo.com logoVanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:VNDA)
us.rd.yahoo.com - February 17 at 5:04 PM
biz.yahoo.com logoVANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report (NASDAQ:VNDA)
biz.yahoo.com - February 17 at 5:04 PM
streetinsider.com logoPoint72 Asset Management, LP Raises Stake in Vanda Pharmaceuticals, Inc. (VNDA) to 5% - StreetInsider.com (NASDAQ:VNDA)
www.streetinsider.com - February 17 at 6:29 AM
sg.finance.yahoo.com logoVanda reports 4Q loss (NASDAQ:VNDA)
sg.finance.yahoo.com - February 17 at 6:29 AM
finance.yahoo.com logoEdited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT (NASDAQ:VNDA)
finance.yahoo.com - February 17 at 6:29 AM
News IconEquity in Focus: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Rives Journal (NASDAQ:VNDA)
rivesjournal.com - February 14 at 8:48 PM
News IconStock Tracker: Earnings & Estimates for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Aiken Advocate (NASDAQ:VNDA)
aikenadvocate.com - February 14 at 3:47 PM
baystreet.ca logoVanda Pharmaceuticals (VNDA) Gains with Q4 Results Due (NASDAQ:VNDA)
www.baystreet.ca - February 9 at 6:34 AM
feeds.benzinga.com logo25 Stocks Moving In Wednesday's Pre-Market Session (NASDAQ:VNDA)
feeds.benzinga.com - February 8 at 8:54 AM
News IconInvesting Focus: Indicators in View on Shares of Vanda Pharmaceuticals Inc. (VNDA) - Market Point (NASDAQ:VNDA)
mtptnews.com - January 30 at 3:47 PM
4-traders.com logoVanda Pharmaceuticals : Expected to Post q2 2017 Earnings of ($0.04) Per Share (Vnda) (NASDAQ:VNDA)
www.4-traders.com - January 30 at 10:04 AM
News IconEarnings in Full Force, Analysts Take Aim at Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - January 27 at 3:47 PM
News IconStock Perspective: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Company Earnings Watch - Aiken Advocate (NASDAQ:VNDA)
aikenadvocate.com - January 24 at 3:22 PM
News IconWatching the Charts on Vanda Pharmaceuticals Inc. (VNDA) - Sherwood Daily (NASDAQ:VNDA)
sherwooddaily.com - January 20 at 3:32 PM
finance.yahoo.com logoVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017 (NASDAQ:VNDA)
finance.yahoo.com - January 19 at 9:07 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - January 18 at 3:44 PM
News IconCCI, ADX, and Williams %R Review for Vanda Pharmaceuticals Inc. (VNDA) - Sherwood Daily (NASDAQ:VNDA)
sherwooddaily.com - January 17 at 3:47 PM
finance.yahoo.com logoMerck KGaA Expands Distribution Deal with Roche (revised) (NASDAQ:VNDA)
finance.yahoo.com - January 17 at 3:47 PM
realistinvestor.com logoQuarterly Deferred Tax Assets Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) At $0.182 Millions - RealistInvestor.com (NASDAQ:VNDA)
www.realistinvestor.com - January 15 at 7:59 PM
News IconWill The Needle Move For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - January 13 at 3:42 PM
investornewswire.com logoSentiments And Ratings Alert: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Investor Newswire (NASDAQ:VNDA)
www.investornewswire.com - January 11 at 3:29 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and - PR Newswire (press release) (NASDAQ:VNDA)
www.prnewswire.com - January 10 at 9:03 PM
News IconVanda Pharmaceuticals, Inc. (NASDAQ:VNDA) Institutional Ownership stands at 94.6 - The Newburgh Press (NASDAQ:VNDA)
newburghpress.com - January 10 at 4:01 PM
streetinsider.com logoVanda Pharmaceuticals (VNDA) Issues Q4, 2016 and 2017 Financial Guidance (NASDAQ:VNDA)
www.streetinsider.com - January 9 at 8:54 PM
marketexclusive.com logoVANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Results of Operations and Financial Condition (NASDAQ:VNDA)
marketexclusive.com - January 9 at 8:54 PM
streetinsider.com logoVanda Pharmaceuticals (VNDA) Issues Q4, 2016 and 2017 Financial Guidance - StreetInsider.com (NASDAQ:VNDA)
www.streetinsider.com - January 9 at 3:51 PM
finance.yahoo.com logoVanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance (NASDAQ:VNDA)
finance.yahoo.com - January 9 at 3:51 PM
biz.yahoo.com logoVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur (NASDAQ:VNDA)
biz.yahoo.com - January 9 at 3:51 PM
finance.yahoo.com logo7:20 am Vanda Pharma follow up: Sees Q4 rev just below consensus; FY17 rev below consensus (NASDAQ:VNDA)
finance.yahoo.com - January 9 at 3:51 PM
News IconInteresting VNDA Put And Call Options For February 17th (NASDAQ:VNDA)
www.stockoptionschannel.com - January 6 at 6:29 AM
News IconPresident and CEO of Vanda Pharmaceuticals Inc (NASDAQ:VNDA), Polymeropoulos Mihael Hristos, sells 23,330 shares worth $361,242 (NASDAQ:VNDA)
empowerednews.net - January 6 at 6:29 AM
finance.yahoo.com logoAbbott Labs to Close St. Jude Acquisition Later this Week (NASDAQ:VNDA)
finance.yahoo.com - January 2 at 8:43 AM
capitalcube.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : January 2, 2017 (NASDAQ:VNDA)
www.capitalcube.com - January 2 at 8:43 AM
finance.yahoo.com logoCempra (CEMP) Gets CRL from FDA for Pneumonia Candidate (NASDAQ:VNDA)
finance.yahoo.com - December 30 at 3:32 PM
News IconVanda Pharmaceuticals Inc. (NASDAQ: VNDA) Rating Reiterated at ... - BNB Daily (blog) (NASDAQ:VNDA)
www.baseball-news-blog.com - December 29 at 1:42 AM
News IconInvestor Watch: Looking at Shares of Vanda Pharmaceuticals Inc ... - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - December 29 at 1:42 AM
investornewswire.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:VNDA)
www.investornewswire.com - December 28 at 8:23 AM
us.rd.yahoo.com logoWhy Vanda Pharmaceuticals (VNDA) Might Be a Diamond in the Rough (NASDAQ:VNDA)
us.rd.yahoo.com - December 27 at 8:11 PM
News IconNarrowing in on the Numbers for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - December 26 at 7:39 PM
News IconMarket Focus: Checking Up on Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - December 26 at 8:19 AM
News IconWatching the Levels: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Beacon (NASDAQ:VNDA)
wsbeacon.com - December 24 at 1:35 AM
stocksdaily.net logoCan Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Post EPS Of $-0.07? - Stocks Daily (NASDAQ:VNDA)
www.stocksdaily.net - December 21 at 8:26 PM

Social

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?

6 brokers have issued 12 month target prices for Vanda Pharmaceuticals' stock. Their predictions range from $18.00 to $24.00. On average, they expect Vanda Pharmaceuticals' share price to reach $21.33 in the next twelve months.

When will Vanda Pharmaceuticals announce their earnings?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LLC (9.56%), Patrick Lee, MD (9.56%), Deerfield Management Co. (7.79%), State Street Corp (3.99%), FMR LLC (2.27%) and Integrated Core Strategies (US) LLC (2.10%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi, Richard L Gulino and Richard W Dugan.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Oxford Asset Management, Acuta Capital Partners LLC, Bogle Investment Management L P DE, Allianz Asset Management AG, Deerfield Management Co., State Board of Administration of Florida Retirement System and RidgeWorth Capital Management LLC. Company insiders that have sold Vanda Pharmaceuticals stock in the last year include James E Flynn and Richard L Gulino.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Numeric Investors LLC, Russell Investments Group Ltd., State Street Corp, Axiom International Investors LLC DE, Renaissance Technologies LLC, Castleark Management LLC and Palo Alto Investors LLC.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vanda Pharmaceuticals stock cost?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $13.85.

Vanda Pharmaceuticals (NASDAQ:VNDA) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Earnings History Chart

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Dividend History Chart

Dividend Payments by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Last Updated on 2/23/2017 by MarketBeat.com Staff